Relmada Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 20
- Market Cap
- $82M
- Website
- http://www.relmada.com
- Introduction
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC
- Conditions
- Non Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06663137
- Locations
- 🇮🇱
Relmada Site, Raanana, Israel
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
- Conditions
- Major Depressive DisorderDepression
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06011577
- Locations
- 🇺🇸
Relmada Site, Seattle, Washington, United States
Individual Patient Esmethadone (REL-1017) Expanded Access Program
- Conditions
- Major Depressive DisorderDepression
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Registration Number
- NCT06009003
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT05081167
- Locations
- 🇺🇸
Relmada Site, Austin, Texas, United States
Safety of REL-1017 for Major Depressive Disorder
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Relmada Therapeutics, Inc.
- Target Recruit Count
- 627
- Registration Number
- NCT04855760
- Locations
- 🇺🇸
Relmada Site, Staten Island, New York, United States
- Prev
- 1
- 2
- Next
News
Major Depressive Disorder Pipeline Advances with 75+ Companies Developing Novel Therapies
A comprehensive pipeline report reveals over 75 companies are developing innovative treatments for major depressive disorder, with several promising candidates advancing through Phase III trials.
Relmada Therapeutics Secures Licensing for Novel Bladder Cancer Treatment NDV-01
Relmada Therapeutics has acquired exclusive worldwide rights to NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, with Phase 2 data expected in April 2025.
Relmada Therapeutics Halts REL-1017 Depression Trials, Explores Strategic Alternatives
Relmada Therapeutics discontinues Phase 3 trials (RELIANCE II and RELIGHT) of REL-1017 for depression after unfavorable data monitoring committee evaluation.
Relmada's Phase 3 Trial of REL-1017 for Major Depressive Disorder Fails Interim Analysis
Relmada Therapeutics' Phase 3 Reliance II trial of REL-1017 as an adjunctive treatment for major depressive disorder is unlikely to meet its primary efficacy endpoint.
Relmada Therapeutics Anticipates Key Interim Analysis for REL-1017 in MDD
Relmada Therapeutics is advancing REL-1017 for major depressive disorder (MDD), with interim analysis results expected by the end of 2024.
Relmada Therapeutics Awaits Key Data and Initiates New Study Amidst Financial Concerns
Relmada Therapeutics anticipates interim analysis results from its Reliance II study for major depressive disorder by year-end.
Relmada Therapeutics Announces Positive Progress in MDD and Metabolic Disease Programs
Relmada Therapeutics anticipates an interim analysis of its Phase 3 Reliance II trial for REL-1017 in major depressive disorder by the end of 2024, marking a potential de-risking event.